54
Participants
Start Date
March 31, 1998
Primary Completion Date
October 31, 2005
Study Completion Date
February 29, 2008
filgrastim
filgrastim (G-CSF) subcutaneously on days 5-21 and 28-42. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
cyclophosphamide
Oral cyclophosphamide on days 22-26. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
etoposide
Oral etoposide on days 1-3. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
lomustine
Oral lomustine on day 1 (course 1 only). Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
procarbazine hydrochloride
Oral procarbazine on days 22-26. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
Herbert Irving Comprehensive Cancer Center at Columbia University, New York
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland
University of Nairobi College of Health Sciences, Nairobi
Uganda Cancer Institute, Kampala
National Cancer Institute (NCI)
NIH
Case Comprehensive Cancer Center
OTHER